Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,020,930
  • Shares Outstanding, K 181,934
  • Annual Sales, $ 2,176 M
  • Annual Income, $ 613,670 K
  • 60-Month Beta 0.82
  • Price/Sales 13.30
  • Price/Cash Flow 41.39
  • Price/Book 8.17
Trade SGEN with:

Options Overview Details

View History
  • Implied Volatility 35.64%
  • Historical Volatility 32.94%
  • IV Percentile 13%
  • IV Rank 13.57%
  • IV High 66.83% on 02/05/21
  • IV Low 30.74% on 08/02/21
  • Put/Call Vol Ratio 0.19
  • Today's Volume 781
  • Volume Avg (30-Day) 447
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 3,690
  • Open Int (30-Day) 7,199

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.53
  • Number of Estimates 10
  • High Estimate -0.25
  • Low Estimate -0.64
  • Prior Year 3.50
  • Growth Rate Est. (year over year) -115.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
147.47 +14.71%
on 09/08/21
172.50 -1.94%
on 08/26/21
+9.86 (+6.19%)
since 08/20/21
3-Month
139.08 +21.63%
on 07/27/21
172.50 -1.94%
on 08/26/21
+10.48 (+6.60%)
since 06/22/21
52-Week
133.20 +27.00%
on 05/04/21
213.94 -20.93%
on 10/13/20
-12.79 (-7.03%)
since 09/22/20

Most Recent Stories

More News
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.

BIIB : 289.32 (-2.10%)
BMY : 60.15 (-0.30%)
INCY : 69.59 (-8.51%)
EXEL : 20.20 (-0.64%)
SGEN : 169.16 (+2.52%)
VRCA : 11.26 (+2.09%)
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

VRTX : 184.27 (-0.82%)
SGEN : 169.16 (+2.52%)
SPRO : 19.28 (+1.31%)
GMAB : 44.04 (-0.50%)
Stocks Give Up Early Gains on Continued Chinese Debt Concerns

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 4,395.64 (+0.95%)
SPY : 437.86 (+0.98%)
$DOWI : 34,258.32 (+1.00%)
DIA : 342.50 (+1.00%)
$IUXX : 15,176.51 (+0.99%)
QQQ : 369.57 (+0.93%)
COP : 62.26 (+4.94%)
AZO : 1,683.76 (+2.48%)
SGEN : 169.16 (+2.52%)
DIS : 173.65 (+1.45%)
ATVI : 72.81 (-0.30%)
ZNZ21 : 132-290 (unch)
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer

The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

VRTX : 184.27 (-0.82%)
SGEN : 169.16 (+2.52%)
SPRO : 19.28 (+1.31%)
GMAB : 44.04 (-0.50%)
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK(TM) (tisotumab vedotin-tftv) Approval

Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK(TM) (tisotumab vedotin-tftv). Access...

SGEN : 169.16 (+2.52%)
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK(TM) (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK(TM) (tisotumab vedotin-tftv), the first...

GMAB : 44.04 (-0.50%)
SGEN : 169.16 (+2.52%)
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK(TM) (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

--- New Monotherapy Approved for Use in a Cancer with Limited Treatment Options -

SGEN : 169.16 (+2.52%)
GMAB : 44.04 (-0.50%)
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

--- Tisotumab Vedotin in Combination with Pembrolizumab Showed Encouraging, Durable Anti-Tumor Activity in Previously Treated Patients -

SGEN : 169.16 (+2.52%)
GMAB : 44.04 (-0.50%)
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021 at 2:00...

SGEN : 169.16 (+2.52%)
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021

Seagen Inc. (Nasdaq: SGEN) today announced data and trials in progress from its diverse and growing portfolio of marketed and investigational therapies will be presented at the virtual European Society...

SGEN : 169.16 (+2.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Seagen Inc. is a biotechnology company. It discovers, develops and commercializes transformative cancer medicines. The company operates principally in California, Canada, Switzerland and the European Union. Seagen Inc., formerly known as Seattle Genetics Inc., is headquartered in the Seattle.

See More

Key Turning Points

3rd Resistance Point 178.63
2nd Resistance Point 174.24
1st Resistance Point 171.70
Last Price 169.16
1st Support Level 164.77
2nd Support Level 160.38
3rd Support Level 157.84

See More

52-Week High 213.94
Fibonacci 61.8% 183.10
Fibonacci 50% 173.57
Last Price 169.16
Fibonacci 38.2% 164.04
52-Week Low 133.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar